Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas

NCT03600649 is registered in ClinicalTrials.gov with Salarius Pharmaceuticals, LLC as lead sponsor.

NCT NCT03600649
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03600649 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Lead sponsor
Salarius Pharmaceuticals, LLC
Phase
Phase 1
Overall status
Unknown status
Start date
June 4, 2018
Completion date
December 31, 2025
Enrollment
50 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

angiomatoid fibrous histiocytoma, clear cell sarcoma, desmoplastic small round cell tumor, ewing sarcoma, extraskeletal myxoid chondrosarcoma, fibromyxoid tumor, myoepithelial tumor, myxoid liposarcoma, primary pulmonary myxoid sarcoma, sarcoma,soft tissue, sclerosing epithelioid fibrosarcoma